Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest earnings release,

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years.